These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 35799400)

  • 1. [Administration Period of Olanzapine as an Antiemetic Drug for Patients on FEC Therapy-A Survey].
    Tsurushima K; Yanagishita Y; Ogawa N; Fujii C; Yasui Y; Takeda T; Tsubaki M; Nishida S; Ishizaka T; Yamamura J; Kamigaki S
    Gan To Kagaku Ryoho; 2022 Jun; 49(6):701-704. PubMed ID: 35799400
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Study protocol for a double-blind, comparative, randomised Japanese trial of triplet standard antiemetic therapies with or without 5 mg olanzapine to prevent chemotherapy-induced nausea and vomiting for patients with breast cancer treated with an anthracycline/cyclophosphamide regimen (JTOP-B).
    Ozeki R; Iihara H; Shimokawa M; Hashimoto H; Abe M; Mukohara T; Bando H; Hayashi T; Kawazoe H; Komoda M; Yanai Takahashi T; Saito M
    BMJ Open; 2022 Mar; 12(3):e058755. PubMed ID: 35236735
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized, double-blind, placebo-controlled study evaluating the efficacy of combination olanzapine, ondansetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving doxorubicin plus cyclophosphamide.
    Tienchaiananda P; Nipondhkit W; Maneenil K; Sa-Nguansai S; Payapwattanawong S; Laohavinij S; Maneechavakajorn J
    Ann Palliat Med; 2019 Sep; 8(4):372-380. PubMed ID: 31500422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized study of olanzapine-containing versus standard antiemetic regimens for the prevention of chemotherapy-induced nausea and vomiting in Chinese breast cancer patients.
    Yeo W; Lau TK; Li L; Lai KT; Pang E; Cheung M; Chan VT; Wong A; Soo WM; Yeung VT; Tse T; Lam DC; Yeung EW; Ng KP; Tang NL; Tong M; Suen JJ; Mo FK
    Breast; 2020 Apr; 50():30-38. PubMed ID: 31978815
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of 5 mg olanzapine combined with aprepitant, granisetron and dexamethasone to prevent carboplatin-induced nausea and vomiting in patients with gynecologic cancer: A multi-institution phase II study.
    Iihara H; Shimokawa M; Hayasaki Y; Fujita Y; Abe M; Takenaka M; Yamamoto S; Arai T; Sakurai M; Mori M; Nakamura K; Kado N; Murase S; Shimaoka R; Suzuki A; Morishige KI
    Gynecol Oncol; 2020 Mar; 156(3):629-635. PubMed ID: 31926638
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low Dose Olanzapine in the Prevention and Treatment of Carboplatin Induced Nausea and Vomiting: A Prospective Clinical Randomized Controlled Trial.
    An Y; Zhang Z; Gu M; Zhao J; Jiang C; Zhao L; Jiang Y; Li H; Liu G; Jin G; Li Q
    Curr Pharm Des; 2023; 29(23):1867-1874. PubMed ID: 37539930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Olanzapine Administration Reduces Chemotherapy-Induced Nausea Behavior in Rats.
    Jaime-Lara RB; Borner T; Holland RA; Shaulson E; Brooks B; De Jonghe BC
    Biol Res Nurs; 2021 Oct; 23(4):584-595. PubMed ID: 33789505
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Olanzapine as antiemetic drug in oncology: a retrospective study in non-responders to standard antiemetic therapy.
    Slimano F; Netzer F; Borget I; Lemare F; Besse B
    Int J Clin Pharm; 2018 Oct; 40(5):1265-1271. PubMed ID: 29744791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Control of Nausea and Vomiting in Patients Receiving Anthracycline/Cyclophosphamide Chemotherapy for Breast Cancer.
    Nawa-Nishigaki M; Kobayashi R; Suzuki A; Hirose C; Matsuoka R; Mori R; Futamura M; Sugiyama T; Yoshida K; Itoh Y
    Anticancer Res; 2018 Feb; 38(2):877-884. PubMed ID: 29374715
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized trial of individualized versus standard of care antiemetic therapy for breast cancer patients at high risk for chemotherapy-induced nausea and vomiting.
    Clemons M; Dranitsaris G; Sienkiewicz M; Sehdev S; Ng T; Robinson A; Mates M; Hsu T; McGee S; Freedman O; Kumar V; Fergusson D; Hutton B; Vandermeer L; Hilton J
    Breast; 2020 Dec; 54():278-285. PubMed ID: 33242754
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Assessment of nausea and vomiting during FEC regimen for breast cancer after the novel antiemetic agent - introduction using MASCC antiemesis tool].
    Oshiro C; Kamigaki S; Nakamura Y; Arai T; Kanai Y; Fujino M; Fujii C; Hamaguchi Y; Iseki C; Hachino Y; Furukawa H
    Gan To Kagaku Ryoho; 2012 Feb; 39(2):241-4. PubMed ID: 22333635
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multicentre, randomised, double-blind, placebo-controlled phase II study of prophylactic olanzapine for patients with metastatic breast cancer receiving T-DXd treatment: protocol for the ERICA study (WJOG14320B).
    Sakai H; Tsurutani J; Ozaki Y; Ishiguro H; Nozawa K; Watanabe K; Maeda S; Yokoe T; Imamura CK; Matsumoto K; Iwasa T; Chiba Y; Takiguchi D; Takano T
    BMJ Open; 2023 Apr; 13(4):e070304. PubMed ID: 37012013
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A prospective audit on the use of prophylactic antiemetics and rates of CINV in patients receiving carboplatin AUC≥4 or combination anthracycline-cyclophosphamide.
    Lo E; Anderson M; Carroll R; Forgeson G; Isaacs R; Jordan J; Satterthwaite L; Wewala N; Fernando J
    N Z Med J; 2021 Apr; 134(1533):33-45. PubMed ID: 33927422
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Olanzapine for the Prevention and Treatment of Chemotherapy-Induced Nausea and Vomiting: A Review to Identify the Best Way to Administer the Drug.
    Zhang XL; Ying JE
    Curr Oncol; 2022 Oct; 29(11):8235-8243. PubMed ID: 36354710
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of olanzapine for breast cancer patients resistant to triplet antiemetic therapy with nausea due to anthracycline-containing adjuvant chemotherapy.
    Sato J; Kashiwaba M; Komatsu H; Ishida K; Nihei S; Kudo K
    Jpn J Clin Oncol; 2016 May; 46(5):415-20. PubMed ID: 26951840
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identifying an optimal antiemetic regimen for patients receiving anthracycline and cyclophosphamide-based chemotherapy for breast cancer--an inspection of the evidence base informing clinical decision-making.
    Hutton B; Clemons M; Mazzarello S; Kuchuk I; Skidmore B; Ng T
    Cancer Treat Rev; 2015 Dec; 41(10):951-9. PubMed ID: 26442474
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized double-blind comparison of ondansetron and metoclopramide in the prophylaxis of emesis induced by cyclophosphamide, fluorouracil, and doxorubicin or epirubicin chemotherapy.
    Bonneterre J; Chevallier B; Metz R; Fargeot P; Pujade-Lauraine E; Spielmann M; Tubiana-Hulin M; Paes D; Bons J
    J Clin Oncol; 1990 Jun; 8(6):1063-9. PubMed ID: 2140854
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Phase II study of palonosetron, aprepitant, dexamethasone and olanzapine for the prevention of cisplatin-based chemotherapy-induced nausea and vomiting in patients with thoracic malignancy.
    Nakashima K; Murakami H; Yokoyama K; Omori S; Wakuda K; Ono A; Kenmotsu H; Naito T; Nishiyama F; Kikugawa M; Kaneko M; Iwamoto Y; Koizumi S; Mori K; Isobe T; Takahashi T
    Jpn J Clin Oncol; 2017 Sep; 47(9):840-843. PubMed ID: 28633504
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Feasibility of olanzapine, multi acting receptor targeted antipsychotic agent, for the prevention of emesis caused by continuous cisplatin- or ifosfamide-based chemotherapy.
    Bun S; Yonemori K; Akagi T; Noguchi E; Shimoi T; Shimomura A; Yunokawa M; Shimizu C; Fujiwara Y; Makino Y; Hayashi Y; Tamura K
    Invest New Drugs; 2018 Feb; 36(1):151-155. PubMed ID: 28733700
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Asenapine versus olanzapine for the treatment of nausea and vomiting in patients with cancer: A retrospective study.
    Kimura T; Kanai A; Muraoka H; Takahashi Y; Ara M; Inada K
    Neuropsychopharmacol Rep; 2024 Mar; 44(1):158-164. PubMed ID: 38239112
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.